Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

Summary

The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality settings in Côte. The cross-sectional study will be carried out in conjunction with a single trachoma MDA in selected villages within one health district. Data on feasibility and acceptability will be collected through three main activities: 1. Analyses of existing routine monitoring, process, and adverse drug reaction data from the trachoma MDA platform into which the pilot activities are being integrated 2. A cross-sectional, post-MDA coverage survey 3. Qualitative data collection among targeting parents or primary caregivers of children ages 1 to 11 months in the pilot districts, and district-level MDA implementers, regarding the proposed azithromycin program.

Timeline

Start

2020-11-20

Primary completion

2021-01-31

Completion

2021-01-31

Publications

• Dulli L, Toure F, Mama AD, Evens E, Murray K, Dje NN, Kone S, Sadate-Ngatchou P, Bovary A, Eichleay M, Jean-Baptiste M, Meite A. Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Cote d'Ivoire. PLOS Glob Public Health. 2024 Jul 10;4(7):e0003426. doi: 10.1371/journal.pgph.0003426. eCollection 2024.

Drugs

Indications

No indication recorded.